DALLAS, April 26,
2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ:
LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence (A.I.) and
machine learning (ML) platform to transform the cost, pace, and
timeline of oncology drug discovery and development, today
announced that Maria L. Maccecchini, Ph.D. has been named as a
nominee for election to Lantern's Board of Directors. Dr.
Maccecchini will be presented alongside a slate of five existing
Directors at Lantern's upcoming Annual Meeting to be held on
June 8, 2022.
Additionally, Leslie W. Kreis,
Jr., the Managing Principal at Steelhead Capital Management,
LLC, managing partner and co-founder of Bios Equity Partners, LP
and Bios Equity Partners II, LP, and a member of Lantern Pharma's
Board of Directors since 2019, has advised Lantern's Board of his
determination not to stand for reelection as a Director at
Lantern's Annual Meeting.
"On behalf of the Board and Lantern Pharma, I would like to
thank Les for his years of input, counsel, and expertise that has
guided Lantern through its journey from a novel idea to a
well-funded, Nasdaq-listed, A.I.-focused biopharma company. He has
helped Lantern through multiple phases of growth — from a private
company, through the IPO, and during the company's continued
progress and improvements in more recent quarters," commented
Panna Sharma, President and CEO of
Lantern Pharma.
"I also want to congratulate Dr. Maccecchini on her
nomination to our Board of Directors. The Board and the Company's
Management are looking forward to her guidance and the opportunity
to benefit from her decades of experience. Her nomination to
Lantern Pharma's Board of Directors comes at an exciting time in
our development, especially as several of our programs are entering
clinical trials. As a seasoned pharma executive, scientist, and
entrepreneur, she will bring multiple areas of expertise to our
Company and be able to advise Lantern on critical decisions about
trial partnering, trial design, and clinical operations" added Mr.
Sharma.
Dr. Maccecchini has over 30 years of biopharmaceutical
experience in the development of novel therapies for Alzheimer's,
Parkinson's, and other neurodegenerative diseases. She is the
founder of Annovis Bio. (Nasdaq: ANVS), a company dedicated to
treating neurodegenerative conditions, and has served as its
President, Chief Executive Officer, and Director since 2008. With
her leadership, Annovis Bio has established a proven track record
of advancing drug programs through multiple phases of clinical
development and currently has 2 programs in or entering phase 3
human clinical trials. She previously served as the founder and CEO
of Symphony Pharmaceuticals/Annovis, which was sold in 2001 to
Transgenomic. In addition to her corporate roles, she has served as
a partner and director of two angel groups, Robin Hood Ventures and
MidAtlantic capital, has been a lecturer at the Wharton Business
School since 2016, and serves on the boards of organizations that
promote entrepreneurship, international trade, and women.
Dr. Maccecchini holds a Ph.D. in Biochemistry and M.Sc. in
Biochemistry and Cell Biology from the University of Basel, has held two Postdoctoral fellowship
positions at the Roche Basel Institute of Technology and at the
California Institute of Technology,
performed research in the distinguished labs of Nobel Laureates
Susumu Tonegawa, Ph.D., and Gunter
Blobel, M.D., Ph.D., and studied corporate finance at the
Wharton Business School.
"It's a pleasure to be welcomed as a nominee to Lantern's board
at such an exciting time when their drug programs are advancing
through different stages of clinical development," said Dr.
Maccecchini. "Lantern is one of only a select number of biopharma
companies successfully utilizing A.I. and big data to develop
targeted oncology therapies. By doing so, they have the potential
to bring precision therapies to patients faster, at lower costs,
and for indications with unmet clinical needs in cancer. I believe
that with Lantern's strategic A.I. approach to drug development,
seasoned leadership team, and pipeline of promising drugs, they are
well-positioned for success."
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is
a clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. and machine
learning platform to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across nine disclosed tumor
targets, including two phase 2 programs. By targeting drugs to
patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes.
Contact:
Nicole Leber
Investor Relations Associate
ir@lanternpharma.com
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA
marketing approval or otherwise been incorporated into a commercial
product, and (v) those other factors set forth in the Risk Factors
section in our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the
Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for
the year ended December 31, 2021
under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov. Given
these risks and uncertainties, we can give no assurances that our
forward-looking statements will prove to be accurate, or that any
other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
Important Additional Information and Where to Find
It
This Press Release may be deemed to contain solicitation
material in respect of the solicitation of proxies from the
stockholders of Lantern Pharma Inc. (the "Company") in connection
with the Company's 2022 annual meeting of stockholders (the "Annual
Meeting"). The Company plans promptly to file with the Securities
and Exchange Commission (the "SEC") its definitive proxy statement
in connection with the Annual Meeting. The definitive proxy
statement will contain important information about the Company, the
Annual Meeting and related matters. Lantern Pharma, its
directors and its executive officers may be deemed to be
participants in the solicitation of proxies from the Company's
stockholders in connection with the Annual Meeting. Information
regarding the names of the Company's directors and executive
officers and their respective interests in the Company will be set
forth in the Company's definitive proxy statement and other
relevant solicitation materials filed by the
Company. Stockholders may obtain a free copy of the Company's
definitive proxy statement and other documents that the Company
files with the SEC (when available) on the SEC's website,
at www.sec.gov. Copies will also be available at no
charge on the Company's website
at www.lanternpharma.com. INVESTORS AND STOCKHOLDERS ARE
URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT
SOLICITATION MATERIALS (WHEN THEY BECOME AVAILABLE) BECAUSE THESE
DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharmas-board-of-directors-names-maria-maccecchini-phd-as-a-director-nominee-to-lanterns-board-of-directors-301532648.html
SOURCE Lantern Pharma